Page 99 - Read Online

Sell et al. Mini-invasive Surg 2024;8:3 https://dx.doi.org/10.20517/2574-1225.2023.105 Page 7 of 10

sinonasal malignancy, but the great diversity of the biology and behavior of sinonasal cancers can make it
difficult to construct broad guidelines or generalizable surveillance protocols. Risk factors, including
staging, histology, tumor grade, and others, should direct the frequency and length of follow-up until more
studies are conducted on sinonasal malignancies. Overall, physicians should be mindful that sinonasal
malignancies are unique among head and neck cancers and often require a tailored and nuanced
surveillance strategy for optimal patient care.

DECLARATIONS
Authors’ contributions
Literature review, manuscript preparation, and manuscript revisions: Sell EA
Review design, literature review, manuscript preparation, and manuscript revisions: Panara K
Review design, manuscript preparations and revisions: Workman AD
Review conception, manuscript preparations and revisions: Adappa ND

Availability of data and materials
All referenced sources are available via Pubmed (https://pubmed.ncbi.nlm.nih.gov/).

Financial support and sponsorship
Adappa ND is funded by the grant titlted “Immune function of bitter taste receptors in human
macrophages” (R01AI167971).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Abdou R, Baredes S. Population-based results in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin
North Am 2017;50:481-97. DOI PubMed
2. Sharma RK, Irace AL, Schlosser RJ, et al. Conditional and overall disease-specific survival in patients with paranasal sinus and nasal
cavity cancer: improved outcomes in the endoscopic era. Am J Rhinol Allergy 2022;36:57-64. DOI PubMed
3. Mirghani H, Mortuaire G, Armas GL, et al. Sinonasal cancer: analysis of oncological failures in 156 consecutive cases. Head Neck
2014;36:667-74. DOI PubMed
4. Li X, Li J, Di B, et al. [Recurrence and surgical salvage of sinonasal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing
Wai Ke Za Zhi 2013;48:186-90. PubMed
5. Bossi P, Hermsen M, Lechner M, Franchi A. Precision medicine in rare tumors and the need for multicenter trials and international
collaboratives: sinonasal cancer as paradigm. Oral Oncol 2020;109:104737. DOI PubMed
6. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal
sinuses. Head Neck 2002;24:821-9. DOI PubMed
7. Harvey RJ, Pitzer G, Nissman DB, et al. PET/CT in the assessment of previously treated skull base malignancies. Head Neck
2010;32:76-84. DOI PubMed
8. de Visscher AVM, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the
larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994;120:934-9. DOI PubMed
9. Dutta R, Dubal PM, Svider PF, Liu JK, Baredes S, Eloy JA. Sinonasal malignancies: a population-based analysis of site-specific